Rapport Therapeutics, Inc. Common Stock (RAPP NASDAQ) stock market data APIs
$35.2857
2.11(6%)
as of May 18, 2026
Try our APIs with
free plan!
Rapport Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Prev. Close
35.2857
Open
37.3916
High
38.1587
Low
34.868
52 wk Range
7.73-42.269
Market Cap
1 773 M
Shares Outstanding
47 827 K
Revenue
20 000 K
EPS
-0.42
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Rapport Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Rapport Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Rapport Therapeutics, Inc. Common Stock Fundamental Data
Rapport Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue: 20 000 K
- EBITDA: -121 206 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Rapport Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: -0.7083
Get Rapport Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Rapport Therapeutics, Inc. Common Stock News
New
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
On April 17, 2026, Third Rock Ventures V, L.P., a 10% owner of Rapport Therapeutics, Inc.(NASDAQ:RAPP), reported the direct sale of 426,005 shares in an open-market transaction valued at approximately...
Rapport's RAP-219 Shows Sustained Seizure Reduction Beyond Treatment Period
(RTTNews) - Rapport Therapeutics, Inc. (RAPP) reported that its investigational therapy RAP-219 continued to deliver clinically meaningful benefits even after dosing ended, with patients experiencing ...
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clin...
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
Cormorant Asset Management disclosed a buy of 2,361,260 shares of MoonLake Immunotherapeutics(NASDAQ:MLTX) in its February 17, 2026 SEC filing, an estimated $27.86 million trade based on quarterly ave...
Get Rapport Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
